A 24-week Open-label Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)

Kissei

Status and phase: Completed; Phase 3

Conditions: Spinocerebellar Degeneration

Treatments: Drug: KPS-0373, Low dose; Drug: KPS-0373, High dose

Study type: Interventional

Funder types: Industry

Identifiers

NCT01970137

KPS1304

Details and patient eligibility

About

The purpose of this study is to evaluate the safety, efficacy, and pharmacokinetics of KPS-0373 in SCD patients (Experience of clinical trials of KPS-0373)

Sex: All

Ages: 20+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Japanese SCD patients with ataxia (Experience of clinical trials of KPS-0373)

Exclusion criteria

• Patients with secondary ataxia
• Patients with clinically significant hepatic, renal, or cardiovascular dysfunction
• Discontinuations in another clinical trials caused by side effects

Trial design

0 participants in 1 patient group

KPS-0373

Experimental group

Treatment:

Drug: KPS-0373, Low dose

Drug: KPS-0373, High dose